MyCrops have developed a vision diagnostics platform that uses algorithms, AI & deep learning to remotely identify hot spots of potential plant health issues and to determine optimal plant maturity. Additional platform features provide a significant increase in the bottom line. In today’s CannaCAST IL episode, Assaf Gavish, co-founder, and CSO of MyCrops introduces the platform and its many benefits. Cultivators interested in learning more about MyCrops, as well as potential investors are invited to reach out to Assaf at: [email protected] , MyCrops website: https://www.mycrops.ag/

Grow Director, led by Dima Chernobilsky, Co-Founder & CEO, have simplified and automated the process of growing medical grade cannabis to enable consistent growing of your optimal growth protocol, with minimal intervention so that you can start the system and come back only when the entire growth cycle is complete. Grow Director’s platform also includes a community feature that enables home-growers to share their protocols and knowledge. Potential distributors who are cannabis insiders in their markets, as well as potential investors are invited to reach out to Dima at: [email protected] , Grow Director website: https://growdirector.com/

GemmaCert, led by Guy Setton, PhD., Co-Founder & CEO, has disrupted the cannabis testing industry with a portable, user-friendly & affordable device for testing cannabis potency that provides results in under 5 minutes. GemmaCert devices have been sold in 30 countries on 6 continents – setting the standard for diagnostic on-site solutions. Guy offers us insights into the key success factors that enabled their success. Potential distributors who are cannabis insiders in their markets, as well as potential investors are invited to reach out to Guy at [email protected], GemmaCert website: https://gemmacert.com/

Today we host Yaron Shoob, Founder and CEO of Elixie SL. Yaron and his team have solved the challenges of both rapid onset and high bioavailability without smoking or vaping – Elixie SL’s Personalized Sublingual Delivery System. The Elixie SL device utilizes a dynamic release mechanism in which the rate of release is determined by the individual’s personal anatomy. Potential investors or strategic partners looking to collaborate are invited to reach out to Yaron at: [email protected], Elixie SL website: https://www.elixie.tech/

Today we interviewed Moav Gafni, Co-founder and Business Development Manager of Cannabotech, a biopharmaceutical company with a focus on the prevention and treatment of cancer, chronic pain and inflammation using botanical elements from medicinal mushrooms and cannabinoids. Everything about Cannabotech is innovative – their wellness products, their personalization technology, their pharmaceutical formulas, and wearable medical device, and even their capital-raising strategy! Moav invites potential strategic partners, research collaboration partners, distributors, and potential investors to reach out at [email protected] Cannabotech website: https://www.cannabotech.com/

Today we host Dr. Kobi Buxdorf, Founder and CEO of Cannadorf. Kobi reveals to us how Cannadorf is able to sidestep all growing obstacles and manufacture cannabis in a closed biological environment to produce sterile, all-natural, full-spectrum pharma-grade cannabis, with consistently identical profiles every single time. Potential pharma companies or cannabis-based drug developers looking to collaborate are invited to reach out to Kobi at [email protected], Cannadorf website: https://cannadorf.com/

In today’s podcast, we interview Avihu Tamir, Founder, and CEO of Kanabo Research. Kanabo has developed an innovative medical-grade vaporization device that provides metered doses at a standard of safety and quality that physicians can trust. The vaporization device uses only 100% pure extracted pharmaceutical-grade cannabis with no added carriers or additives, with formulations targeted at specific medical indications. Potential distributors, as well as research partners looking to perform clinical trials using Kanabo’s platform, are invited to reach out at [email protected] Kanabo website: https://www.kanabogroup.com/

In this episode, Clifton Flack, founder, and CEO of CiiTech, reveals a revolutionary approach to weight loss that’s not centered around appetite suppression. CiiTech is conducting research centered around Fatty Liver Disease, Obesity, and Diabetes. Once patent approval is attained, Ciitech will launch a food supplement version of their unique cannabinoid formulation, while continuing the clinical studies to complete and launch a pharma version of the treatment. Learn about their unique approach and two-pronged mechanism in today’s podcast. Interestingly, though CiiTech currently sells and distributes its line of food supplements in the UK, Clifton has chosen to conduct the research and clinical studies in Israel. In his words: “in addition to Israel’s vast data & experience in medical cannabis research and Israel’s medical innovation mentality, costs of the entire process are significantly more attractive in Israel.” POTENTIAL GLOBAL DISTRIBUTORS interested in distributing the food supplement version, as well as SMART INVESTORS that can add value to the pharma solution are invited to reach out to Clifton at: [email protected] https://ciitech.co.il/

In this episode, Dr. Orna Dreazen, chairperson of Nextage Cannabis Innovations and Nextar ChemPharma Solutions tells us about breakthrough developments coming out of Nextage. Nextage has developed nanotechnology that enables the penetration of various drugs, including cannabinoids, into the blood brain barrier, exhibiting both safety and efficacy. Dr. Dreazen also describes exciting developments with some of the rare cannabinoids such as CBN. Investors, as well as potential licensing partners, are welcome to reach out to Dr. Dreazen at [email protected] Nextage Cannabis Innovation Center https://nextageinnovation.com/ Nextar ChemPharma Solutions https://www.nextar.co.il/

In our new episode, we spoke with Dr. Arnon Heyman, PhD in Plant Biotechnology and CEO of Canonic, a subsidiary of Evogene. Canonic brings new genetics to the cannabis market using a Computational Predictive Biology (CPB) platform which enables them to use Big Data and AI to reach insights within the plant genetics for specific medical indications. Arnon recommends addressing three key industry pains: genetic stability, compound yield and active compounds via the plant genetics. Canonic is a subsidiary of Evogene Ltd. (NASDAQ, TASE: EVGN), the company’s strategy includes the development of Cannabis varieties in order to commercialize medical Cannabis products independently or through collaborations. Canonic has exclusive access to Evogene’s genomic assets and technology for the development of medical Cannabis products. Investors, distributors or growers interested in collaboration are invited to reach Arnon are invited at: [email protected] Canonic’s website: www.canonicbio.com